Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Immunomedics : Leaps Despite Q1 Loss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:27pm CET
Immunomedics, Inc. (NASDAQ: IMMU) shares spiked in Friday trading on first quarter numbers Total costs and expenses for the first quarter ended September 30, 2017 were $22.3 million, compared to $15.7 million for the same quarter in fiscal 2017, an increase of approximately 42%. Net loss attributable to stockholders was $118.7 million, or approximately $0.97 per share, for the first quarter ended September 30, 2017, compared to $16.2 million, or approximately $0.17 per share, for the same quarter in fiscal 2017, an increase of approximately 633%. Cash, cash equivalents, and marketable securities totaled $139.6 million as of September 30, 2017. Chairman Behzad Aghazadeh said, “During the quarter and over the course of the year, we have made significant progress toward preparing a BLA for accelerated approval of IMMU-132, our breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). "IMMU-132 has shown a remarkable response rate in patients and we remain sharply focused on bringing this promising treatment to market as soon as possible. Notably, in the quarter, we completed a number of successful meetings with the (Food and Drug Administration) including a CMC and a pre-BLA meeting, where we received positive feedback on our proposed submission plans. As such, we remain on track to meet our stated goal of submitting our BLA filing in the first quarter.” Shares gained $2.03, or 19.4%, to $12.47.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
01/19 IMMUNOMEDICS : Data on Monoclonal Antibodies Discussed by Researchers at Immunom..
01/19 IMMUNOMEDICS : Findings from Immunomedics, Inc. Has Provided New Data on Melanom..
01/12 IMMUNOMEDICS : Announces Agreement with University of Wisconsin Carbone Cancer C..
01/11 Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer ..
01/10 IMMUNOMEDICS, INC. : Today’s Research Reports on Stocks to Watch: Immunomedics, ..
01/09 IMMUNOMEDICS : and Royalty Pharma Announce Royalty Funding and Stock Purchase Ag..
01/08 IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Unregistered Sale..
01/08 Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase A..
01/04 Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017 IMMUNOMEDICS : Entry into a Material Definitive Agreement (form 8-K/A)
More news
News from SeekingAlpha
01/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 12, 2018
01/12 Immunomedics (IMMU) Presents At 36th Annual J.P. Morgan Healthcare Conference..
01/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 11, 2018
01/11 Immunomedics to fund mid-stage study of sacituzumab govitecan in CRPC
01/10 When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
Financials ($)
Sales 2018 14,9 M
EBIT 2018 -101 M
Net income 2018 -197 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 164x
Capi. / Sales 2019 60,0x
Capitalization 2 431 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 18,3 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Michael Pehl President & Chief Executive Officer
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
William A. Wegener Chief Medical Officer
David M. Goldenberg Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.-1.05%2 431
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423
LONZA GROUP0.76%20 876
INCYTE CORPORATION-4.65%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 275